Combination therapy shows promise for drug-resistant acute lymphoblastic leukemia in mice

A team of scientists from Case Western Reserve University School of Medicine (OH, USA) have developed a novel treatment combination for drug-resistant acute lymphoblastic leukemia (ALL). In this study, the researchers investigated the B-cell activating factor receptor (BAFF-R), which is present on drug-resistant ALL cells, as a flag to attract natural killer immune cells in order to destroy the cancerous cells.Studying the effect in vivo, the team found that this technique provided survival benefit and significantly decreased ALL disease burden. The findings were recently published in Cancer Immunology Research. “If we started to treat mice with the antibody early during...